Screener
Rapport Therapeutics, Inc. RAPP Offering Costs
Offering Costs at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rapp:OfferingCosts.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
FAQ
- What is Rapport Therapeutics, Inc.'s offering costs?
- Rapport Therapeutics, Inc. (RAPP) reported offering costs of -$180K in Q2 2026.
- How has Rapport Therapeutics, Inc.'s offering costs changed year-over-year?
- Rapport Therapeutics, Inc.'s offering costs decreased by 168.7% year-over-year, from $262K to -$180K.
- What does offering costs mean?
- Includes direct costs incurred in connection with equity or debt offerings, such as legal, accounting, and printing fees that are not otherwise netted against proceeds. Monitoring these costs is important for evaluating the efficiency of the company's capital-raising activities. High offering costs relative to proceeds may indicate inefficient financing execution.
Ask your AI about Rapport Therapeutics, Inc.'s offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude